Cresset, innovative provider of software and contract research services for small molecule discovery and design, and Cancer Therapeutics CRC (CTx), a collaborative partnership of leading research institutes, universities and biotechnology companies in Australia, will co-exhibit on stand 66 at AusBiotech 2017, Adelaide, Australia on 25-27 October.
Delegates attending AusBiotech 2017 will learn how the power of Cresset’s virtual screening platform, Blaze, combined with the experience of CTx, makes a powerful and effective platform for lead discovery. Specifically: finding novel hits that are not found using other methods; consistently returning hits with lower molecular weight than other approaches; and increasing wet screening hit rates at a fraction of the cost.
“We have been consistently impressed with the computational methods we’ve used from Cresset,” says Dr Graeme Stevenson, Group Leader, CTx. “Blaze has streamlined our discovery workflow, saving us time and money and helping us identify new lead compounds.”
“CTx plays a pivotal role in the discovery of cancer-related targets and therapeutic compounds,” says Dr David Bardsley, Commercial Director, Cresset. “We’re looking forward to sharing the successes of our partnership and explaining how we have worked together to streamline the discovery of novel hits. We will also be demonstrating Flare, our new structure-based design application, on stand 66 at AusBiotech 2017.”
Cresset: Sue Peffer, Marketing Manager, firstname.lastname@example.org, +44 (0)1223 858890
Cancer Therapeutics CRC: Warwick Tong, CEO, email@example.com, +61 (3) 9077 0809
Cresset’s software and discovery research services are used by chemists from the world’s leading research organizations. Our patented methods deliver novel, realistic results for discovering, designing and optimizing the best small molecules in industry sectors including: agrochemicals, fine chemicals, flavor, fragrance and pharmaceuticals. For more information visit www.cresset-group.com
About Cancer Therapeutics CRC (CTx)
Founded in 2007 and supported through the Australian GovernmenttCooperative Research Centre (CRC) Programme, CTx is a small molecule, oncology focussed, drug discovery and development biotechnology group.
Through its unique partnership model with Australian Research Institutes, Universities and end user companies, CTx leverages Australia’s top cancer research minds and facilities to discover and develop new therapies for patients.
CTx's unparalleled domain expertise, deep technical skills and a suite of eResearch technologies has resulted In CTX successfully out-licensing multiple programs. For more information visit www.cancercrc.com